On March 5, 2025, the U.S. District Court for the Northern District of Texas denied the Outsourcing Facilities Association’s motion for a ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Ignore the noise in GLP-1 stocks. Find the best value instead.

Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...

The Outsourcing Facilities Association is appealing a ruling that rejected their request for an injunction against the FDA’s ...

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...

We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at ...

Roller-coaster healthcare stock Hims & Hers Health (NYSE: HIMS), whose stock got devastated last week by worries that it ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...